Century Therapeutics (IPSC) Stock Statistics & Valuation Metrics

Century Therapeutics has a market cap or net worth of $43.17M. The enterprise value is -$49.67M.

Century Therapeutics has 86,045,040 shares outstanding. The number of shares has decreased by -2.65% in one year.

Century Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Century Therapeutics is -1.44. Century Therapeutics’s PEG ratio is -1.09.

In the last 12 months, Century Therapeutics had revenue of 2.23M and earned -136.67M in profits. Earnings per share was -2.30.

In the last 12 months, operating cash flow was -112.14M and capital expenditures -980.00K, giving a free cash flow of -113.12M billion.

Century Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Century Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.

Century Therapeutics as a current ratio of 9.92, with Debt / Equity ratio of 27.90%

In the past 12 months, Century Therapeutics has paid 1.88M in taxes.

Century Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Century Therapeutics has $198.11M in cash and marketable securities with $48.17M in debt, giving a net cash position of -$143.52M billion.

Gross margin is -404.17%, with operating margin of -6556.87%, and net profit margin of -6115.12%.

The average price target for Century Therapeutics is $4.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy